2024.02.07

Agreement marks an important milestone to advance the Company's intent to become a U.S. -based biotech  Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing